银屑病生物制剂治疗后湿疹化发生机制及应对策略

doi:10.35541/cjd.20220578

中华皮肤科杂志 ›› 2024, e20220578.doi: 10.35541/cjd.20220578

银屑病生物制剂治疗后湿疹化发生机制及应对策略

宗杨永怡马楚君苏忠兰

江苏省人民医院皮肤科，南京 210029

收稿日期:2022-08-18 修回日期:2023-08-30 发布日期:2024-03-01
通讯作者: 苏忠兰 E-mail:suzhonglan@jsph.org.cn
基金资助:
国家自然科学基金（81773326）

Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management

Zong Yangyongyi, Ma Chujun, Su Zhonglan

Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Received:2022-08-18 Revised:2023-08-30 Published:2024-03-01
Contact: Su Zhonglan E-mail:suzhonglan@jsph.org.cn
Supported by:
National Natural Science Foundation of China（81773326）

摘要/Abstract

摘要： 【摘要】生物制剂治疗银屑病后，部分病例可能出现湿疹样皮疹。本文阐明银屑病生物制剂治疗后湿疹化可能的发生机制，并总结湿疹化应对策略。局部或系统使用糖皮质激素治疗可以使部分湿疹化病情得到较好控制；而有些情况下可以停药或者换用其他类型生物制剂，甚至加用免疫抑制剂、度普利尤单抗或磷酸二酯酶4抑制剂等。

关键词: 银屑病, 生物制剂, 湿疹, 皮炎, 特应性, 治疗, 发病机制

Abstract: 【Abstract】 Eczematous dermatitis may occur in some patients with psoriasis following biological therapy. This review elucidates potential pathological mechanisms underlying this phenomenon and summarizes strategies for managing eczematization. Topical or systemic glucocorticoid treatment can effectively control some eczematous conditions; in some cases, discontinuation or switching to another types of biologic agents may be considered, especially the combination of immunosuppressants, dupilumab, or phosphodiesterase-4 inhibitors.

Key words: Psoriasis, Biological agents, Eczema, Dermatitis, atopic, Therapy, Pathogenesis

宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024,e20220578. doi:10.35541/cjd.20220578

Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management[J]. Chinese Journal of Dermatology,2024,e20220578. doi:10.35541/cjd.20220578

参考文献 47

［1］	王宇, 杨斌. 银屑病与特应性皮炎的T细胞免疫失衡机制研究进展［J］. 皮肤性病诊疗学杂志, 2021,28（3）:232⁃236. doi：10.3969/j.issn.1674⁃8468.2021.03.019.
［2］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［3］	Driessen RJ, Berends MA, Boezeman JB, et al. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome［J］. Br J Dermatol, 2008,158（5）:1098⁃1106. doi: 10.1111/j.1365⁃2133.2008.08514.x.
［4］	Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study （UNCOVER⁃J）［J］. J Dermatol, 2017,44（4）:355⁃362. doi: 10.1111/1346⁃8138.13622.
［5］	Liakos W, Toussi A, Le ST, et al. Anti⁃interleukin 23⁃based therapies may shift cutaneous immune responses: a case of new⁃onset contact dermatitis to carbamates after guselkumab for psoriasis［J］. Dermatitis, 2021,32（6）:e113⁃e115. doi: 10.1097/DER.0000000000000765.
［6］	Martinez⁃Mera C, González MA, Hospital M, et al. Isothiazolinones in paint as a cause of airborne contact dermatitis in a patient with psoriasis receiving anti⁃interleukin⁃17 therapy［J］. Contact Dermatitis, 2019,80（5）:328⁃329. doi: 10.1111/cod.13203.
［7］	Dhonncha EN，Razali Q，Roche L，et al. Erythroderma following ustekinumab therapy for psoriasis［J］. Br J Dermatol, 2018,179（S1）:25.
［8］	Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1440⁃1448. doi: 10.1111/jdv.16246.
［9］	Bennett AN, Wong M, Zain A, et al. Adalimumab⁃induced asthma［J］. Rheumatology （Oxford）, 2005,44（9）:1199⁃1200. doi: 10. 1093/rheumatology/keh676.
［10］	Chan JL, Davis⁃Reed L, Kimball AB. Counter⁃regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy［J］. J Drugs Dermatol, 2004,3（3）:315⁃318.
［11］	Pagan⁃Leon S, Werbel T, Montanez⁃Wiscovich M. Tumor necrosis factor inhibitor⁃induced eczematous eruption: a report of two cases and review of the literature［J］. Cureus, 2021,13（5）:e15078. doi: 10.7759/cureus.15078.
［12］	Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis［J］. Nat Commun, 2018,9（1）:25. doi: 10.1038/s41467⁃017⁃02466⁃4.
［13］	Psarras A, Antanaviciute A, Alase A, et al. TNF⁃α regulates human plasmacytoid dendritic cells by suppressing IFN⁃α production and enhancing T cell activation［J］. J Immunol, 2021,206（4）:785⁃796. doi: 10.4049/jimmunol.1901358.
［14］	Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti⁃interleukin 17 treatment of psoriasis: an emerging condition［J］. Br J Dermatol, 2019,181（3）:604⁃606. doi: 10.1111/bjd.17779.
［15］	Munera⁃Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:e40⁃e42. doi: 10.1111/jdv.15156.
［16］	Brembilla NC, Senra L, Boehncke WH. The IL⁃17 family of cytokines in psoriasis: IL⁃17A and beyond［J］. Front Immunol, 2018,9:1682. doi: 10.3389/fimmu.2018.01682.
［17］	Karamanakos A, Vergou T, Panopoulos S, et al. Psoriasis as an adverse reaction to biologic agents beyond anti⁃TNF⁃α therapy［J］. Eur J Dermatol, 2021,31（3）:307⁃317. doi: 10.1684/ejd. 2021.4056.
［18］	Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis［J］. J Am Acad Dermatol, 2022,86（5）:1080⁃1091. doi: 10.1016/j.jaad.2020.12.010.
［19］	Weidinger S, Willis⁃Owen SA, Kamatani Y, et al. A genome⁃wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis［J］. Hum Mol Genet, 2013,22（23）:4841⁃4856. doi: 10.1093/hmg/ddt317.
［20］	Mendes Roncada EV, Brambilla VR, Freitas Filitto B, et al. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis［J］. Case Rep Dermatol, 2021,13（2）:336⁃339. doi: 10.1159/000513467.
［21］	Abe F, Mitsuyama S, Nagao E, et al. Atopic dermatitis⁃like eruption induced by two different biologics in a patient with psoriatic arthritis［J］. Acta Derm Venereol, 2019,99（13）:1291⁃1292. doi: 10.2340/00015555⁃3321.
［22］	Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report［J］. SAGE Open Med Case Rep, 2020,8:2050313X20904561. doi: 10.1177/2050313X20904561.
［23］	Arevalo M, Fonseca E, Nespereira M, et al. Eczema⁃like reactions induced by tumor necrosis factor⁃α antagonist agents［J］. J Am Acad Dermatol, 2013,68（4, Supplement 1）: AB180. doi: 10.1016/j.jaad.2012.12.743
［24］	Dumont⁃Berset M, Laffitte E, Gerber C, et al. Eczematous drug eruption after infliximab［J］. Br J Dermatol, 2004,151（6）:1272⁃1273. doi: 10.1111/j.1365⁃2133.2004.06282.x.
［25］	Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis［J］. JAAD Case Rep, 2019,5（11）:973⁃975. doi: 10.1016/j.jdcr.2019.09.005.
［26］	Napolitano M, Gallo L, Patruno C, et al. Eczematous reaction to ixekizumab successfully treated with dupilumab［J］. Dermatol Ther, 2020,33（2）:e13218. doi: 10.1111/dth.13218.
［27］	Koschitzky M, Tan K, Noliza Encarnacion MR, et al. Eczematous reactions to psoriasis biologics treated with dupilumab: a case series［J］. JAAD Case Rep, 2021,11:29⁃32. doi: 10.1016/j.jdcr. 2021.03.006.
［28］	Chicharro P, Rodríguez⁃Jiménez P, De la Fuente H, et al. Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti⁃IL⁃17 therapy［J］. J Allergy Clin Immunol Pract, 2020,8（10）:3619⁃3621.e1. doi: 10.1016/j.jaip.2020.06.064.
［29］	Lai F, Higgins E, Smith CH, et al. Morphologic switch from psoriasiform to eczematous dermatitis after anti⁃IL⁃17 therapy: a case series［J］. JAMA Dermatol, 2019,155（9）:1082⁃1084. doi: 10.1001/jamadermatol.2019.1268.
［30］	Peera M, Smith A. Palmoplantar pompholyx secondary to interleukin 17A inhibitor therapy for psoriasis: a case series［J］. JAAD Case Rep, 2021,13:46⁃48. doi: 10.1016/j.jdcr.2021.03. 052.
［31］	Lai F, Pink A, Higgins E, et al. Phenotypic switch from psoriasis to eczema on anti⁃interleukin⁃17 therapy: a case series［J］. Br J Dermatol, 2019,181（S1）:42⁃43. doi: 10.1111/bjd.17752
［32］	Eichhoff G. Secukinumab⁃induced pompholyx in a psoriasis patient［J］. Dermatol Online J, 2020,26（4）:13030/qt3669k149.
［33］	Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis［J］. Expert Rev Clin Immunol, 2019,15（11）:1205⁃1214. doi: 10.1080/1744666X.2020.1672537.
［34］	Damiani G, Pacifico A, Chu S, et al. Frequency of phototherapy for treating psoriasis: a systematic review［J］. Ital J Dermatol Venerol, 2022,157（3）:215⁃219. doi: 10.23736/S2784⁃8671.21. 06975⁃3.
［35］	Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema［J］. N Engl J Med, 2011,365（3）:231⁃238. doi: 10.1056/NEJMoa1104200.
［36］	Ono S, Honda T, Doi H, et al. Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin［J］. JAAD Case Rep, 2018,4（5）:429⁃433. doi: 10.1016/j.jdcr. 2017.11.026.
［37］	Park JW, Park SJ, Koh YG, et al. Dupilumab⁃induced palmoplantar psoriasis: is it true psoriasis?［J］. Dermatitis, 2022,33（3）:e33⁃e35. doi: 10.1097/DER.0000000000000824.
［38］	Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434. doi: 10.1111/bjd.20064.
［39］	Beaziz J, Bouaziz JD, Jachiet M, et al. Dupilumab⁃induced psoriasis and alopecia areata: case report and review of the literature［J］. Ann Dermatol Venereol, 2021,148（3）:198⁃201. doi: 10.1016/j.annder.2021.02.003.
［40］	Imafuku S, Maeyama A. Remission of anti⁃tumor necrosis factor⁃α antibody⁃induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis［J］. J Dermatol, 2021,48（5）:e240⁃e241. doi: 10.1111/1346⁃8138.15860.
［41］	Wang YA, Rosenbach M. Successful treatment of refractory tumor necrosis factor inhibitor⁃induced palmoplantar pustulosis with tofacitinib: report of case［J］. JAAD Case Rep, 2020,6（2）:115⁃118. doi: 10.1016/j.jdcr.2019.12.006.
［42］	Licata G, Gambardella A, Tancredi V, et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib［J］. J Eur Acad Dermatol Venereol, 2022,36（2）:e150⁃e152. doi: 10.1111/jdv.17705.
［43］	Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis［J］. J Dermatolog Treat, 2020,31（1）:33⁃40. doi: 10.1080/09546634.2019.1577549.
［44］	Kvist⁃Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review［J］. Dermatol Ther （Heidelb）, 2020,10（1）:29⁃42. doi: 10.1007/s13555⁃019⁃00347⁃w.
［45］	Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56⁃week data from the randomized controlled phase 3 SELECT⁃PsA 2 study［J］. Rheumatol Ther, 2021,8（2）:903⁃919. doi: 10.1007/s40744⁃021⁃00305⁃z.
［46］	Hayakawa M, Izumi K, Higashida⁃Konishi M, et al. Tocilizumab⁃induced psoriasis⁃like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case⁃based review［J］. Rheumatol Int, 2019,39（1）:161⁃166. doi: 10.1007/s00296⁃018⁃4175⁃1.
［47］	Cacabelos R, Naidoo V, Corzo L, et al. Genophenotypic factors and pharmacogenomics in adverse drug reactions［J］. Int J Mol Sci, 2021,22（24）:13302. doi: 10.3390/ijms222413302.

[1]	陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 84-88.
[2]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会老年皮肤病学组. [开放获取] 老年皮肤瘙痒症诊疗与康复专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 1-8.
[3]	中国康复医学会皮肤病康复专业委员会中国康复医学会光动力治疗与康复专业委员会中华医学会皮肤性病学分会光动力治疗协作组. [开放获取] 氨基酮戊酸光动力疗法治疗非黑色素瘤皮肤癌临床应用专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 9-19.
[4]	廖彩荷王佩茹吴明顺孙晓飞张国龙王秀丽. 联合氨基酮戊酸光动力疗法治疗老年颜面部基底细胞癌的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 34-39.
[5]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[6]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.
[7]	杨子靖陈利红阮叶平文莞廷张嘉艺王海伦潘萌赵肖庆. 度普利尤单抗治疗老年性特应性皮炎的疗效及安全性研究[J]. 中华皮肤科杂志, 2025, 58(1): 65-69.
[8]	王迪张瑞珺康玉英. 脂溢性皮炎的发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 89-92.
[9]	王瑞霞曲岩磊艾文锦闫琳曲才杰史同新. 非大疱性嗜中性红斑狼疮1例[J]. 中华皮肤科杂志, 2024, 57(9): 832-834.
[10]	向茜张凌燕钟琳高奕邱逦. 鲜红斑痣多模态超声表现及在光动力疗效评估中的应用研究[J]. 中华皮肤科杂志, 2024, 57(9): 801-806.
[11]	乔嘉熙夏萍陈柳青. 司库奇尤单抗治疗前后银屑病局部皮损皮肤镜和反射式共聚焦显微镜特征分析[J]. 中华皮肤科杂志, 2024, 57(9): 825-829.
[12]	任伟琦邹雅茹潘敏. 大疱性类天疱疮患者继发感染危险因素的研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 770-772.
[13]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 57(8): 743-746.
[14]	夏曼琪邵蕾黄琼霄田歆梁毅敏黄婷梁景耀刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684.
[15]	罗莉张博娜吴畏汤文静李岳华刘晓莉马雅楠李翠翠齐梦岩孙妮石琼. [开放获取] 308 nm准分子激光与308 nm准分子光治疗194例儿童白癜风的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2024, 57(8): 721-727.

银屑病生物制剂治疗后湿疹化发生机制及应对策略

Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

Metrics

本文评价

推荐阅读 10